what Novartis India paid Pfizer Inc for the Minipress brand, over its annual sales
Pfizer India's Q2 FY27 profit: ₹132 crore for a ₹1,250 crore brand
Pfizer Ltd's net profit rose 66% to ₹313 crore in Q2 FY27, according to its 3 November results. But much of this came from a one-time payment. ₹132 crore was paid by its American parent, Pfizer Inc, because Pfizer India had to stop selling a drug. Without this payment, profit per share grew 14%, roughly in line with sales growth of 13%.
Pfizer India sells medicines in the country, many of which use brand names owned by its American parent. One of these was Minipress XL, a medicine used to treat high blood pressure and prostate problems. It generated ₹228.6 crore in sales in the year to July 2026, according to IQVIA. Pfizer Inc decided to stop making the drug, so Pfizer India stopped selling it on 7 September. In return, the Indian company received $13.9 million, or about ₹131 crore.
But there is more to the story. On the same day, Novartis India announced that it had bought the Indian rights to the Minipress brand from Pfizer Inc for ₹1,250 crore. Novartis says it has enough stock and has arranged fresh supplies, so the drug will continue to be available.
The difference is striking. Pfizer India received about ₹131 crore for giving up a brand that generated ₹229 crore in annual sales. Novartis, meanwhile, paid ₹1,250 crore for the same brand, about 5.5 times its annual sales.
The reason is that the brand belonged to Pfizer Inc, not Pfizer India. The Indian company only sold the drug. Now it has lost those sales, and the one-time payment will not be there to boost its profits next quarter.
A third of Pfizer Ltd's Q2 FY27 pre-tax profit was 1 payment
Profit before tax, July to September 2026, in ₹ crore. 31% of it is Pfizer Inc's payment for dropping Minipress XL.
₹ CRORE, PROFIT BEFORE TAX
- From the business290.77 68.8%
- Minipress XL payment132.06 31.2%
The payment is shown net of related expenses, as an exceptional item.
Pfizer Ltd, results for the quarter ended 30 September 2026, BSE filing of 3 November 2026 · Jul to Sep 2026
Pfizer Inc got 9.5x for Minipress what it paid Pfizer Ltd
What changed hands over Minipress in India on 7 September 2026, in ₹ crore. The parent sold the trademarks; the listed Indian arm gave up selling the drug.
₹ CRORE
Pfizer Ltd's payment is USD 13.9 million, which its filing puts at about ₹131.38 crore.
Pfizer Ltd and Novartis India Ltd, BSE filings of 7 September 2026 · 7 Sep 2026
Minipress XL sold ₹228 crore a year before Pfizer Ltd gave it up
Minipress XL's sales in India, 12 months to July each year, in ₹ crore, by IQVIA's count. The brand holds about 63% of its market.
₹ CRORE, 12 MONTHS TO JULY
IQVIA counts sales into the market at trade prices, not Pfizer Ltd's own revenue from the brand.
Novartis India Ltd, investor presentation, BSE filing of 11 September 2026 (IQVIA TSA data) · Aug 2021 to Jul 2026
Sources
- Pfizer Ltd, unaudited results for the quarter and half year ended 30 September 2026, BSE filing of 3 November 2026 (PDF)
- Pfizer Ltd, outcome of board meeting: discontinuation of Minipress XL, BSE filing of 7 September 2026 (PDF)
- Novartis India Ltd, acquisition of the Minipress and Minipres trademarks from Pfizer Inc, BSE filing of 7 September 2026 (PDF)
- Novartis India Ltd, investor presentation, BSE filing of 11 September 2026 (PDF)
- Novartis India Ltd, transcript of the investor call of 11 September 2026, BSE filing of 15 September 2026 (PDF)